Filing Details

Accession Number:
0001576280-21-000019
Form Type:
4/A
Zero Holdings:
No
Publication Time:
2021-02-17 17:16:23
Reporting Period:
2021-02-02
Accepted Time:
2021-02-17 17:16:23
Original Submission Date:
2021-02-03
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1576280 Guardant Health Inc. GH Services-Medical Laboratories (8071) 454139254
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1753159 Amirali Talasaz 505 Penobscot Drive
Redwood City CA 94063
Chairman, President And Coo Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2021-02-02 43,364 $158.91 2,638,622 No 4 S Direct
Common Stock Disposition 2021-02-02 15,676 $159.54 2,622,946 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
Footnotes
  1. These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
  2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $158.22 to $159.19, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
  3. This amendment corrects minor errors regarding share amounts and/or prices.
  4. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $159.50 to $159.61, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
  5. Reflects updated direct holdings as of 02/02/2021 after giving effect to the corrections to the share amounts.